Literature DB >> 3053065

In vitro and ex vivo enhancement of nonspecific phagocytosis by cefodizime.

A Fietta1, C Bersani, R Bertoletti, F M Grassi, G G Grassi.   

Abstract

The in vitro and ex vivo effects of cefodizime on some functional activities of both human neutrophils and monocytes were studied. In vitro experiments were performed with antibiotic concentrations ranging from 1 to 200 micrograms/ml. For the ex vivo study, 7 adult healthy controls were treated intravenously with 4 g/day of cefodizime for 6 days. We found that the drug modulated phagocytosis frequency and index when nonopsonized zymosan and heat-killed Candida albicans were used as phagocytic challenge both in vitro (from 25 micrograms/ml) and ex vivo 12 h after the last administration of cefodizime. No effect on the other phagocyte functional parameters was shown. The in vitro enhancement of nonspecific phagocytosis was demonstrated both in the presence of cefodizime and when phagocytes and particles were separately incubated with the drug.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3053065     DOI: 10.1159/000238603

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  10 in total

1.  In vitro effect of cefodizime, imipenem/cilastatin and co-trimoxazole on dexamethasone and cyclosporin A depressed phagocytosis.

Authors:  A Dhondt; R Vanholder; M A Waterloos; G Glorieux; R De Smet; S Ringoir
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

Review 2.  Immunomodulating effects of antibiotics: literature review.

Authors:  B Van Vlem; R Vanholder; P De Paepe; D Vogelaers; S Ringoir
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

3.  Influence of cefodizime on pulmonary inflammatory response to heat-killed Klebsiella pneumoniae in mice.

Authors:  Y Bergeron; A M Deslauriers; N Ouellet; M C Gauthier; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

4.  Cefodizime host-defence enhancement: considerations of dose-response relationships in healthy volunteers.

Authors:  G Gialdroni Grassi; P M Shah
Journal:  Infection       Date:  1992       Impact factor: 3.553

5.  Cefodizime: enhancement of depressed phagocytosis-associated respiratory burst activity in chronic uremic patients.

Authors:  R Vanholder; S Ringoir
Journal:  Infection       Date:  1992       Impact factor: 3.553

6.  Changes in lymphocyte subpopulations in patients treated with cefodizime for acute lower respiratory tract infections.

Authors:  Y Valcke; M Van der Straeten
Journal:  Infection       Date:  1992       Impact factor: 3.553

7.  Immunopharmacological activity of cefodizime in young and elderly subjects: in vitro and ex vivo studies.

Authors:  P L Meroni; F Capsoni; M O Borghi; W Barcellini; F Minonzio; A M Ongari; C Fain; C Hu; G Brambilla; C Pettenati
Journal:  Infection       Date:  1992       Impact factor: 3.553

8.  Influence of cefodizime on the reagibility of human leukocytes.

Authors:  M Limbert; H Müllner; P M Shah
Journal:  Infection       Date:  1992       Impact factor: 3.553

Review 9.  Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; R N Brogden
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

10.  Reduction by cefodizime of the pulmonary inflammatory response induced by heat-killed Streptococcus pneumoniae in mice.

Authors:  Y Bergeron; N Ouellet; A M Deslauriers; M Simard; M Olivier; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.